As Johnson & Johnson begins Phase III trials of its COVID-19 vaccine candidate, it has also just released early data suggesting it is effective in generating an immune response in adults of aged 18-65 and over, with no worrying safety problems detected so far.
J&J’s candidate, JNJ-78436735 (also known as Ad26.COV2.S), is being developed primarily as a single vaccination, rather than in a ‘prime...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?